KEAP1 and neoplasm: <i>STK11</i> mutations frequently co-occur with <i>KRAS</i> and <i>KEAP1</i> alterations, exhibit low PD-L1 expression, an immunosuppressive tumor microenvironment that leads to the development of PD-1/PD-L1 resistance.